-
Je něco špatně v tomto záznamu ?
Chemokine receptors and their therapeutic opportunities in diseased lung: far beyond leukocyte trafficking
T. Tomankova, E. Kriegova, M. Liu,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
Grantová podpora
NT11117
MZ0
CEP - Centrální evidence projektů
- MeSH
- antiflogistika farmakologie terapeutické užití MeSH
- cílená molekulární terapie MeSH
- leukocyty fyziologie MeSH
- lidé MeSH
- plíce imunologie metabolismus patologie MeSH
- plicní nemoci farmakoterapie imunologie metabolismus MeSH
- pohyb buněk MeSH
- receptory chemokinů fyziologie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Chemokine receptors and their chemokine ligands, key mediators of inflammatory and immune cell trafficking, are involved in the regulation of both physiological and pathological processes in the lung. The discovery that chemokine receptors/chemokines, typically expressed by inflammatory and immune cells, are also expressed in structural lung tissue cells suggests their role in mediating the restoration of lung tissue structure and functions. Thus, chemokine receptors/chemokines contribute not only to inflammatory and immune responses in the lung but also play a critical role in the regulation of lung tissue repair, regeneration, and remodeling. This review aims to summarize current state-of-the-art on chemokine receptors and their ligands in lung diseases such as chronic obstructive pulmonary disease, asthma/allergy, pulmonary fibrosis, acute lung injury, and lung infection. Furthermore, the therapeutic opportunities of chemokine receptors in aforementioned lung diseases are discussed. The review also aims to delineate the potential contribution of chemokine receptors to the processes leading to repair/regeneration of the lung tissue.
Faculty of Medicine and Dentistry Department of Immunology Palacky University Olomouc Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15022840
- 003
- CZ-PrNML
- 005
- 20190606101704.0
- 007
- ta
- 008
- 150709s2015 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1152/ajplung.00203.2014 $2 doi
- 035 __
- $a (PubMed)25637606
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Tománková, Tereza $u Faculty of Medicine and Dentistry, Department of Immunology, Palacky University Olomouc, Czech Republic; Latner Thoracic Surgery Research Laboratories, Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada; and. $7 xx0199224
- 245 10
- $a Chemokine receptors and their therapeutic opportunities in diseased lung: far beyond leukocyte trafficking / $c T. Tomankova, E. Kriegova, M. Liu,
- 520 9_
- $a Chemokine receptors and their chemokine ligands, key mediators of inflammatory and immune cell trafficking, are involved in the regulation of both physiological and pathological processes in the lung. The discovery that chemokine receptors/chemokines, typically expressed by inflammatory and immune cells, are also expressed in structural lung tissue cells suggests their role in mediating the restoration of lung tissue structure and functions. Thus, chemokine receptors/chemokines contribute not only to inflammatory and immune responses in the lung but also play a critical role in the regulation of lung tissue repair, regeneration, and remodeling. This review aims to summarize current state-of-the-art on chemokine receptors and their ligands in lung diseases such as chronic obstructive pulmonary disease, asthma/allergy, pulmonary fibrosis, acute lung injury, and lung infection. Furthermore, the therapeutic opportunities of chemokine receptors in aforementioned lung diseases are discussed. The review also aims to delineate the potential contribution of chemokine receptors to the processes leading to repair/regeneration of the lung tissue.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antiflogistika $x farmakologie $x terapeutické užití $7 D000893
- 650 _2
- $a pohyb buněk $7 D002465
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a leukocyty $x fyziologie $7 D007962
- 650 _2
- $a plíce $x imunologie $x metabolismus $x patologie $7 D008168
- 650 _2
- $a plicní nemoci $x farmakoterapie $x imunologie $x metabolismus $7 D008171
- 650 _2
- $a cílená molekulární terapie $7 D058990
- 650 _2
- $a receptory chemokinů $x fyziologie $7 D019707
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Kriegová, Eva, $u Faculty of Medicine and Dentistry, Department of Immunology, Palacky University Olomouc, Czech Republic; $d 1968- $7 xx0142572
- 700 1_
- $a Liu, Mingyao $u Latner Thoracic Surgery Research Laboratories, Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada; and Faculty of Medicine, Departments of Physiology, Surgery, and Medicine, Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada mingyao.liu@utoronto.ca.
- 773 0_
- $w MED00000288 $t American journal of physiology. Lung cellular and molecular physiology. Lung cellular and molecular physiology $x 1522-1504 $g Roč. 308, č. 7 (2015), s. L603-618
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25637606 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150709 $b ABA008
- 991 __
- $a 20190606101841 $b ABA008
- 999 __
- $a ok $b bmc $g 1083179 $s 905833
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 308 $c 7 $d L603-618 $i 1522-1504 $m American journal of physiology. Lung cellular and molecular physiology $n Am J Physiol Lung Cell Mol Physiol $x MED00000288 $o Lung cellular and molecular physiology
- GRA __
- $a NT11117 $p MZ0
- LZP __
- $a Pubmed-20150709